Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemia

Félicité de Charry; Johanna Konopacki; Sarah Bugier; Vincent Foissaud; Ivan Sloma; Jean-Valère Malfuson; Pierre Arnautou

doi:10.1016/j.lrr.2023.100366

Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemia

Leuk Res Rep. 2023 Mar 16:19:100366. doi: 10.1016/j.lrr.2023.100366. eCollection 2023.

Authors

Félicité de Charry¹, Johanna Konopacki¹, Sarah Bugier², Vincent Foissaud², Ivan Sloma³, Jean-Valère Malfuson¹, Pierre Arnautou¹

Affiliations

¹ Service d'hématologie, HIA Percy, Clamart, France.
² Service de biologie médicale, HIA Percy, Clamart, France.
³ Département d'hématologie et d'immunologie biologiques, Hôpital Henri Mondor, APHP, Créteil, France.

Abstract

We describe here a 56-years -old woman cured in our institution for an acute myeloid leukemia (AML) and a monoclonal gammopathy of undetermined significance (MGUS). In order to treat AML, underwent allogeneic stem cell transplantation in second complete remission. Four years after transplant, MGUS evolved to multiple myeloma and was intensively treated with "autologous" transplant after successful mobilization. This report illustrates: (i) a lack of efficacy of graft versus myeloma effect in a patient probably cured of AML by graft versus leukaemia effect; (ii) the ability to mobilize peripheral blood stem cells in order to perform "autologous" transplantation after allogeneic transplantation.

Keywords: Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Autologous hematopoietic stem cell transplantation; Multiple myeloma.

Publication types

Case Reports